专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007121920A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2007121920A2
公开(公告)日：2007-11-01
申请号：PCT/EP2007/003435
申请日：2007-04-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , FAIRHURST, Robin, Alec , TAYLOR, Roger, John , COX, Brian
发明人： FAIRHURST, Robin, Alec , TAYLOR, Roger, John , COX, Brian
CPC分类号： C07D473/16 , C07D473/34
摘要： A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals, wherein R 1 , R 2 and R 3 are as defined herein.
摘要翻译：式（I）化合物或其立体异构体或其药学上可接受的盐及其作为药物的制备和用途，其中R 1，R 2和R 3， / SUP>如本文所定义。

2. 发明申请

WO2004096800A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：喹诺酮衍生物与MUCARINIC M3受体结合
公开(公告)号：WO2004096800A2
公开(公告)日：2004-11-11
申请号：PCT/EP2004/004605
申请日：2004-04-30
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , COLLINGWOOD, Stephen, Paul , COX, Brian , BAETTIG, Urs , BHALAY, Gurdip , DEVEREUX, Nicholas, James
发明人： COLLINGWOOD, Stephen, Paul , COX, Brian , BAETTIG, Urs , BHALAY, Gurdip , DEVEREUX, Nicholas, James
IPC分类号： C07D453/02
CPC分类号： C07D453/02
摘要： Compounds of formula (I), in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
摘要翻译：式（I）化合物，其盐或两性离子形式，其中R 1，R 2，R 3和R 4具有说明书中所示的含义，可用于处理是由毒蕈碱M3受体介导的。还描述了含有化合物的药物组合物和制备该化合物的方法。

3. 发明申请

WO2006048225A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：喹啉衍生物及其作为MUSCARINIC M3受体拮抗剂的用途
公开(公告)号：WO2006048225A1
公开(公告)日：2006-05-11
申请号：PCT/EP2005/011662
申请日：2005-10-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , PRESS, Neil, John , COLLINGWOOD, Stephen, Paul , BAETTIG, Urs , COX, Brian , GARAD, Sudhakar, Devidasrao , KIM, Hyungchul , PAPOUTSAKIS, Dimitris , WATSON, Simon, James
发明人： PRESS, Neil, John , COLLINGWOOD, Stephen, Paul , BAETTIG, Urs , COX, Brian , GARAD, Sudhakar, Devidasrao , KIM, Hyungchul , PAPOUTSAKIS, Dimitris , WATSON, Simon, James
IPC分类号： A61K31/439 , C07D453/02 , A61P29/00
CPC分类号： C07D453/02
摘要： Compounds of Formula (I) ; in salt or zwitterionic form wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
摘要翻译：式（I）化合物; 其中R 1，R 2，R 3和R 4的盐或两性离子形式具有如所示的含义在本说明书中，可用于治疗由毒蕈碱M3受体介导的病症，特别是炎性或阻塞性气道疾病。还描述了含有化合物的药物组合物和制备该化合物的方法。

4. 发明申请

WO2006125596A1 ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS 审中-公开
标题翻译：用于治疗易患或过敏症状的有机化合物
公开(公告)号：WO2006125596A1
公开(公告)日：2006-11-30
申请号：PCT/EP2006/004851
申请日：2006-05-22
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , AXFORD, Jake , BAETTIG, Urs , COX, Brian , BALA, Kamlesh, Jagdis , LEBLANC, Catherine , SANDHAM, David, Andrew
发明人： AXFORD, Jake , BAETTIG, Urs , COX, Brian , BALA, Kamlesh, Jagdis , LEBLANC, Catherine , SANDHAM, David, Andrew
IPC分类号： C07D295/16 , A61K31/40 , A61K31/445 , A61P29/00
CPC分类号： C07D295/185
摘要： Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m, n, w, X, and Y have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh 2 receptor, especially inflammatory or obstructive airways diseases.
摘要翻译：游离或药学上可接受的盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，m，n，w，X和Y具有如上所述的含义在本说明书中，可用于治疗由CRTH2受体介导的病症，特别是炎性或阻塞性气道疾病。

5. 发明申请

WO2005123731A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2005123731A2
公开(公告)日：2005-12-29
申请号：PCT/EP2005/006493
申请日：2005-06-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BALA, Kamlesh , LEBLANC, Catherine , SANDHAM, David, Andrew , TURNER, Katharine, Louise , WATSON, Simon, James , BROWN, Lyndon, Nigel , COX, Brian
发明人： BALA, Kamlesh , LEBLANC, Catherine , SANDHAM, David, Andrew , TURNER, Katharine, Louise , WATSON, Simon, James , BROWN, Lyndon, Nigel , COX, Brian
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , A61K31/437 , A61K45/06
摘要： There are provided according to the invention compounds of formula (I), in free or salt form, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
摘要翻译：根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，，Q，W，X，m，n和p如说明书，制备方法及其作为药物的用途所述。

6. 发明申请

WO2007134828A1 PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS 审中-公开
标题翻译： PYRAZOLO [3，4-D]吡哆醛衍生物有助于治疗呼吸道疾病
公开(公告)号：WO2007134828A1
公开(公告)日：2007-11-29
申请号：PCT/EP2007/004501
申请日：2007-05-21
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BRUCE, Ian , HAYLER, Judy, Fox , BLOOMFIELD, Graham, Charles , EDWARDS, Lee , COX, Brian , HOWSHAM, Catherine
发明人： BRUCE, Ian , HAYLER, Judy, Fox , BLOOMFIELD, Graham, Charles , EDWARDS, Lee , COX, Brian , HOWSHAM, Catherine
IPC分类号： A61K31/519 , A61K31/5377 , C07D487/04
CPC分类号： A61K31/519 , A61K31/5377 , C07D487/04
摘要： The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R 1 -R 3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物，其中R 1〜R 3和Y在说明书中定义，其中用于治疗其中涉及pi3激酶的病症。

7. 发明申请

WO2007134827A1 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS 审中-公开
标题翻译： 5-PHENYL-THIAZ0L-2-YL-UREA衍生物和用作PI3激酶抑制剂
公开(公告)号：WO2007134827A1
公开(公告)日：2007-11-29
申请号：PCT/EP2007/004500
申请日：2007-05-21
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BUDD, Emma , FOX HAYLER, Judy , IAN, Bruce , LEGRAND, DArren MArk Novartis Horsham Research Centre , COX, Brian
发明人： BUDD, Emma , FOX HAYLER, Judy , IAN, Bruce , LEGRAND, DArren MArk Novartis Horsham Research Centre , COX, Brian
IPC分类号： C07D277/48 , C07D417/12 , A61K31/427 , A61P11/00
CPC分类号： C07D277/48 , C07D417/12
摘要： The present invention concerns a compound of formula Ia wherein: R a * is hydrogen or C 1 -C 4 -alkyl; R b* is -(C 1 -C 4 -alkylene)-Y-C 1 -C 4 -haloalkyl or -(C 1 -C 4 -alkylene)-Y-C 1 -C 4 -hydroxyalkyl; Y represents -CONH- or a five membered heteroaryl group. R 2* is C 1 -C 4 -alkyl or halogen; R 3* is halo, -SO 2 -CH 3 , -SO 2 -CF 3 , carboxy, -CO-NH 2 , -CO-di(C 1 -C 8 -alkyl)amino, or a 5- or 6- membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C 3 -C 8 -cycloalkyl, C 1 -C 8 -alkylcarbonyl, C 1 -C 8 -alkoxy optionally substituted by aminocarbonyl, or C 1 -C 8 -alkyl optionally substituted by hydroxy, C 1 - C 8 -alkoxy, C 1 - C 8 -alkylamino or di(C 1 - C 8 -alkyl)amino; R 4* is hydrogen, halo, -SO 2 -CH 3 , nitrile, C 1 - C 8 -haloalkyl, imidazolyl, C 1 - C 8 -alkyl, -NR 8* R 9* , or -SO 2 -NR 8* R 9* ; and R 5* is hydrogen, halogen or C 1 - C 8 -alkyl; R 8* and R 9* are independently hydrogen, amino, C 1 - C 8 -alkylamino, di(C 1 - C 8 -alkyl)amino, or CC 1 - C 8 -alkyl optionally substituted by hydroxyl; or a pharmaceutically acceptable salt, or solvate thereof, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
摘要翻译：本发明涉及式Ia化合物，其中：R a a *是氢或C 1 -C 4 - 烷基; R 1是 - （C 1 -C 4 - 亚烷基）-YC 1 -C 3 - 4 - 卤代烷基或 - （C 1 -C 4 - 亚烷基）-YC 1 -C 4 - SUB> - 羟基烷基; Y表示-CONH-或五元杂芳基。 R 2是C 1 -C 4 - 烷基或卤素; R 3是卤素，-SO 2 -CH 3，-SO 2 -CF 3 羧基，-CO-NH 2，-CO-二（C 1 -C 8 - 烷基）氨基，或具有一个或多个选自氧，氮和硫的环杂原子的5-或6-元杂环，该环任选被卤素，氰基，氧代，羟基，羧基，硝基，C C 3 -C 8 - 环烷基，C 1 -C 8 - 烷基羰基，C 1〜任选被氨基羰基取代的C 8 - 烷氧基或任选被羟基取代的C 1 -C 8 - 烷基，C 1〜 C 1 -C 8 - 烷氧基，C 1 -C 8 - 烷基氨基或二（C 1 -C 6 - 烷基） _{8 - 烷基）氨基; R 4是氢，卤素，-SO 2 -CH 3，腈，C 1 -C 3烷基， 9个 - 卤代烷基，咪唑基，C 1 -C 8 - 烷基，-NR 8 * 9 或，或-SO 2 2 -NR 8 * 9 9 * 和R 5 *是氢，卤素或C 1 -C 8 - 烷基; R 8 *和R 9 *独立地是氢，氨基，C 1 -C 8 - 烷基氨基，二（C 1 -C 8 - 烷基）氨基或任选被下述基团取代的C 1 -C 8 - 烷基羟; 或其药学上可接受的盐或溶剂合物，用于治疗通过抑制磷脂酰肌醇3-激酶而变质的疾病的组合物和用途。}

8. 发明申请

WO2006125593A1 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2006125593A1
公开(公告)日：2006-11-30
申请号：PCT/EP2006/004844
申请日：2006-05-22
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BAETTIG, Urs , COX, Brian , JANUS, Diana , LEBLANC, Catherine , SANDHAM, David, Andrew , TURNER, Katharine, Louise , WATSON, Simon, James
发明人： BAETTIG, Urs , COX, Brian , JANUS, Diana , LEBLANC, Catherine , SANDHAM, David, Andrew , TURNER, Katharine, Louise , WATSON, Simon, James
IPC分类号： C07C69/708 , C07C235/22 , C07C59/70 , C07C323/20 , C07C317/22 , C07C59/90 , A61K31/216 , A61K31/16 , A61K31/194 , A61P29/00
CPC分类号： C07C317/22 , C07C59/70 , C07C69/712 , C07C205/37 , C07C235/22 , C07C323/20 , C07C2601/02
摘要： A compound of formula (I); in free or pharmaceutically acceptable salt form, where R 1 , R 2 , R 3 , R 4 , R 5 , m, n, w, X, Y and Q have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh 2 receptor, especially inflammatory or obstructive airways diseases.
摘要翻译：式（I）化合物; 其游离或药学上可接受的盐形式，其中R 1，R 2，R 3，R 4，R 4， m，n，w，X，Y和Q具有说明书中所示的含义，可用于治疗由CRTh2受体介导的病症，特别是炎症性或阻塞性气道疾病。

9. 发明申请

WO2003025004A2 NOVEL PURIFIED POLYPEPTIDES INVOLVED IN NUCLEIC ACID PROCESSING 审中-公开
标题翻译：新型纯化多肽在核酸加工中的应用
公开(公告)号：WO2003025004A2
公开(公告)日：2003-03-27
申请号：PCT/CA2002/001411
申请日：2002-09-18
申请人： AFFINIUM PHARMACEUTICALS, INC. , EDWARDS, Aled , DHARAMSI, Akil , VEDADI, Masoud , ALAM, Muhammad, Zahoor , ARROWSMITH, Cheryl , AWREY, Donald , BEATTIE, Bryan , CANADIEN, Veronica , COX, Brian , DOMAGALA, Megan , HOUSTON, Simon , LI, Qin , NETHERY, Kathleen , NG, Ivy , OUYANG, Hui , PINDER, Benjamin , SHELDRICK, Bay , VIOLA, Cristina , WREZEL, Olga
发明人： EDWARDS, Aled , DHARAMSI, Akil , VEDADI, Masoud , ALAM, Muhammad, Zahoor , ARROWSMITH, Cheryl , AWREY, Donald , BEATTIE, Bryan , CANADIEN, Veronica , COX, Brian , DOMAGALA, Megan , HOUSTON, Simon , LI, Qin , NETHERY, Kathleen , NG, Ivy , OUYANG, Hui , PINDER, Benjamin , SHELDRICK, Bay , VIOLA, Cristina , WREZEL, Olga
IPC分类号： C07K14/195
CPC分类号： C07K1/36 , B01D15/361 , B01D15/3804 , B01J41/04 , C07K14/205 , C07K14/21 , C07K14/315 , C07K14/3156 , C07K2319/00 , G01N2030/8804
摘要： The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides.
摘要翻译：本发明涉及致病性细菌的多肽靶标。本发明还提供了这些多肽的生物化学和生物物理特性。

10. 发明申请

WO2002062745A1 USE OF BICYCLIC ESTERS OR AMIDES FOR THE TREATMENT OF DISEASES RESPONSIVE TO ENHANCED POTASSIUM CHANNEL ACTIVITY 审中-公开
标题翻译：用于治疗与增强的钾通道活性有关的疾病的双胞胎或其他药物的使用
公开(公告)号：WO2002062745A1
公开(公告)日：2002-08-15
申请号：PCT/GB2002/000496
申请日：2002-02-04
申请人： GLAXO GROUP LIMITED , COX, Brian , CRYAN, Jennifer, Elizabeth , DALE, Timothy, James , ROBERTSON, Graeme, Michael , TREZISE, Derek, John
发明人： COX, Brian , CRYAN, Jennifer, Elizabeth , DALE, Timothy, James , ROBERTSON, Graeme, Michael , TREZISE, Derek, John
IPC分类号： C07C233/11
CPC分类号： C07D295/185 , A61K31/35 , A61K31/38 , A61K31/44 , A61K31/535 , C07C233/11 , C07C235/34 , C07C2601/02 , C07C2602/08 , C07C2602/10 , C07D215/12 , C07D311/58 , C07D335/06
摘要： A compound of formula (I): or a salt, solvate or physiologically functional derivative thereof for use as a IK and/or SK channel opener. Methods of screening SK ion channels, particularly SK1 and medicaments for the treatment of a urinogenital, respiratory, cardiovascular, neuronal disorder, of sleeping disorders, sickle cell anemia, pain, inflammation and bowel disease (IBD) are also disclosed.
摘要翻译：式（I）化合物或其盐，溶剂合物或生理功能衍生物，用作IK和/或SK通道开放剂。还公开了筛选SK离子通道的方法，特别是SK1和用于治疗睡眠障碍，镰状细胞性贫血，疼痛，炎症和肠病（IBD）的尿中生长，呼吸，心血管，神经元紊乱的药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式